Home Invivo Functional Antibodies Immunology & Inflammation CD markers Anti-mouse 4-1BB (CD137)-InVivo
For research use only. Not for use in humans.

Anti-mouse 4-1BB (CD137)-InVivo

Synonyms: TNFRSF9， CD137 Clone No.：3H3

Anti-mouse 4-1BB (CD137)-InVivo reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137.

Anti-mouse 4-1BB (CD137)-InVivo

Click to purchase the isotype control of Anti-mouse 4-1BB (CD137)-InVivo

2 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 6.45 mg/ml Endotoxin Level: <1EU/mg
99

Product Details

Clone 3H3
Isotype Rat IgG2a
Application Anti-mouse 4-1BB (CD137)-InVivo
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS, pH 7.0 Contains no stabilizers or preservatives
Murine Pathogen Screening Panel all targets tested yielded Negative Results: Theiler’s Murine Encephalomyelitis Virus, Ectromelia (Mousepox) Virus, Hantavirus, Polyomavirus, Sendai Virus, Mycoplasma pulmonis, Pneumonia Virus of Mice, K Virus, Mouse Parvovirus, Mouse Hepatitis Virus, Mouse Norovirus, Mouse Minute Virus, Mouse Cytomegalovirus, Mouse Adenovirus, Lactate Dehydrogenase-Elevating Virus, Reovirus Panel, Lymphocytic Choriomeningitis Virus, Mouse Rotavirus.
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07720180 NOT_YET_RECRUITING Drug: Fludarabine|Drug: Cyclophosphamide Ovarian Cancer Medical University of South Carolina 2026-12-01 PHASE2
NCT06782932 RECRUITING Drug: AGEN2373|Drug: Balstilimab|Drug: Cyclophosphamide|Drug Pancreatic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2025-05-27 PHASE1; PHASE2
NCT04740424 RECRUITING Drug: FS222 Advanced Cancer; Metastatic Cancer invoX Pharma Limited 2020-12-14 PHASE1
NCT06410131 RECRUITING Drug: FTL008.16 Solid Tumors Sound Biopharmaceuticals Ltd. 2025-05-27 PHASE1
NCT04648202 ACTIVE_NOT_RECRUITING Drug: FS120 Advanced Cancer; Metastatic Cancer invoX Pharma Limited 2020-11-18 PHASE1
NCT04635995 COMPLETED Cancer Lyvgen Biopharma Holdings Limited 2020-12-11 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-22)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.